Overview Dividends

(ZTS) Zoetis - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035

Vaccines, Parasiticides, Diagnostics, Dermatology, Anti-Infectives

ZTS EPS (Earnings per Share)

EPS Growth (3Y CAGR): -55.51%
EPS Trend (3Y Correlation): -30.5%

ZTS Revenue

Revenue Growth (3Y CAGR): 7.78%
Revenue Trend (3Y Correlation): 88.4%

Description: ZTS Zoetis September 26, 2025

Zoetis Inc. (NYSE: ZTS) is the world’s largest pure-play animal-health company, covering the full product lifecycle-from discovery and development to manufacturing and commercialization-of medicines, vaccines, diagnostics, biodevices, genetic tests and precision-health solutions for both livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses).

Its portfolio spans parasiticides, vaccines, dermatology, anti-infectives, pain-management and sedation products, as well as point-of-care diagnostics, laboratory kits, blood-glucose monitors and nutritionals. Sales are directed to veterinarians, livestock producers and pet owners, with a growing emphasis on data-driven precision health tools that can improve animal welfare and farm productivity.

Key recent metrics (FY 2023): revenue of $7.1 billion, up ≈ 7 % YoY; adjusted EBITDA margin of ≈ 30 %; and diluted EPS of $4.65. The company’s growth is being driven by rising global protein demand (FAO projects a 30 % increase in meat consumption by 2050) and accelerating adoption of preventive health regimes in intensive-farming operations, which boost vaccine and diagnostic sales.

Zoetis is also expanding its pipeline through collaborations such as the partnership with Blacksmith Medicines to develop novel animal-health antibiotics, addressing both antimicrobial-resistance concerns and the need for new therapeutic classes.

For a deeper quantitative assessment, you might explore ValueRay’s detailed valuation models for ZTS.

ZTS Stock Overview

Market Cap in USD	63,490m
Sub-Industry	Pharmaceuticals
IPO / Inception	2013-02-01

ZTS Stock Ratings

Growth Rating	-35.4%
Fundamental	84.0%
Dividend Rating	70.3%
Return 12m vs S&P 500	-31.5%
Analyst Rating	4.26 of 5

ZTS Dividends

Dividend Yield 12m	1.67%
Yield on Cost 5y	1.58%
Annual Growth 5y	21.23%
Payout Consistency	100.0%
Payout Ratio	33.0%

ZTS Growth Ratios

Growth Correlation 3m	-65.1%
Growth Correlation 12m	-83.9%
Growth Correlation 5y	-13%
CAGR 5y	-0.61%
CAGR/Max DD 3y (Calmar Ratio)	-0.02
CAGR/Mean DD 3y (Pain Ratio)	-0.06
Sharpe Ratio 12m	0.48
Alpha	-38.26
Beta	0.902
Volatility	21.79%
Current Volume	1375.1k
Average Volume 20d	2875.4k
Stop Loss	141.5 (-3%)
Signal	-0.49

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (2.61b TTM) > 0 and > 6% of Revenue (6% = 563.1m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA 0.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 27.25% (prev 49.41%; Δ -22.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.20 (>3.0%) and CFO 2.93b > Net Income 2.61b (YES >=105%, WARN >=100%)

Net Debt (5.36b) to EBITDA (4.04b) ratio: 1.33 <= 3.0 (WARN <= 3.5)

Current Ratio 1.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (445.5m) change vs 12m ago -2.30% (target <= -2.0% for YES)

Gross Margin 70.03% (prev 68.32%; Δ 1.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 65.53% (prev 62.94%; Δ 2.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.18 (EBITDA TTM 4.04b / Interest Expense TTM 234.0m) >= 6 (WARN >= 3)

Altman Z'' 7.05

(A) 0.18 = (Total Current Assets 5.92b - Total Current Liabilities 3.37b) / Total Assets 14.48b

(B) 0.89 = Retained Earnings (Balance) 12.87b / Total Assets 14.48b

warn (B) unusual magnitude: 0.89 — check mapping/units

(D) 1.26 = Book Value of Equity 12.00b / Total Liabilities 9.50b

Total Rating: 7.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.02

1. Piotroski 8.50pt = 3.50

2. FCF Yield 3.22% = 1.61

3. FCF Margin 23.64% = 5.91

4. Debt/Equity 1.36 = 1.64

5. Debt/Ebitda 1.33 = 1.26

6. ROIC - WACC (= 16.12)% = 12.50

7. RoE 53.21% = 2.50

8. Rev. Trend 88.35% = 6.63

9. EPS Trend -30.54% = -1.53

What is the price of ZTS shares?

As of October 27, 2025, the stock is trading at USD 145.94 with a total of 1,375,100 shares traded.
Over the past week, the price has changed by +0.61%, over one month by +1.70%, over three months by -3.19% and over the past year by -19.17%.

Is Zoetis a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Zoetis (NYSE:ZTS) is currently (October 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.02 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZTS is around 129.24 USD . This means that ZTS is currently overvalued and has a potential downside of -11.44%.

Is ZTS a buy, sell or hold?

Zoetis has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy ZTS.

Strong Buy: 10
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ZTS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	188.8	29.4%
Analysts Target Price	188.8	29.4%
ValueRay Target Price	144.1	-1.3%

ZTS Fundamental Data Overview October 18, 2025

Market Cap USD = 63.49b (63.49b USD * 1.0 USD.USD)
P/E Trailing = 24.6575
P/E Forward = 21.692
P/S = 6.7651
P/B = 13.0444
P/EG = 2.1909
Beta = 0.902
Revenue TTM = 9.38b USD
EBIT TTM = 3.55b USD
EBITDA TTM = 4.04b USD
Long Term Debt = 5.23b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last quarter)
Debt = 6.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.36b USD (from netDebt column, last quarter)
Enterprise Value = 68.85b USD (63.49b + Debt 6.79b - CCE 1.44b)
Interest Coverage Ratio = 15.18 (Ebit TTM 3.55b / Interest Expense TTM 234.0m)
FCF Yield = 3.22% (FCF TTM 2.22b / Enterprise Value 68.85b)
FCF Margin = 23.64% (FCF TTM 2.22b / Revenue TTM 9.38b)
Net Margin = 27.83% (Net Income TTM 2.61b / Revenue TTM 9.38b)
Gross Margin = 70.03% ((Revenue TTM 9.38b - Cost of Revenue TTM 2.81b) / Revenue TTM)
Gross Margin QoQ = 72.28% (prev 70.54%)
Tobins Q-Ratio = 4.75 (Enterprise Value 68.85b / Total Assets 14.48b)
Interest Expense / Debt = 0.85% (Interest Expense 58.0m / Debt 6.79b)
Taxrate = 20.40% (184.0m / 902.0m)
NOPAT = 2.83b (EBIT 3.55b * (1 - 20.40%))
Current Ratio = 1.76 (Total Current Assets 5.92b / Total Current Liabilities 3.37b)
Debt / Equity = 1.36 (Debt 6.79b / totalStockholderEquity, last quarter 4.98b)
Debt / EBITDA = 1.33 (Net Debt 5.36b / EBITDA 4.04b)
Debt / FCF = 2.41 (Net Debt 5.36b / FCF TTM 2.22b)
Total Stockholder Equity = 4.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.04% (Net Income 2.61b / Total Assets 14.48b)
RoE = 53.21% (Net Income TTM 2.61b / Total Stockholder Equity 4.91b)
RoCE = 35.03% (EBIT 3.55b / Capital Employed (Equity 4.91b + L.T.Debt 5.23b))
RoIC = 24.62% (NOPAT 2.83b / Invested Capital 11.48b)
WACC = 8.50% (E(63.49b)/V(70.28b) * Re(9.34%) + D(6.79b)/V(70.28b) * Rd(0.85%) * (1-Tc(0.20)))
Discount Rate = 9.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.60%
[DCF Debug] Terminal Value 76.59% ; FCFE base≈2.17b ; Y1≈2.56b ; Y5≈3.92b
Fair Price DCF = 120.0 (DCF Value 53.19b / Shares Outstanding 443.2m; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: -30.54 | EPS CAGR: -55.51% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.35 | Revenue CAGR: 7.78% | SUE: 1.35 | # QB: 1

Additional Sources for ZTS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle